Health & Fitness
Tue, February 10, 2009Mon, February 9, 2009Sun, February 8, 2009Fri, February 6, 2009Thu, February 5, 2009Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Sun, February 1, 2009Sat, January 31, 2009Fri, January 30, 2009Thu, January 29, 2009Wed, January 28, 2009Tue, January 27, 2009CombinatoRx to Present at 11th Annual BIO CEO & Investor Conference
Published in Health and Fitness on Tuesday, February 3rd 2009 at 13:48 GMT, Last Modified on 2009-02-03 13:49:14 by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that Alexis Borisy, President and CEO is scheduled to present at the BIO 11th Annual CEO & Investor Conference on Tuesday, February 10, 2009 at 9:30 AM ET at the Waldorf Astoria in New York City. Interested parties may access a live webcast of the presentation by visiting the CombinatoRx website at [ www.combinatorx.com ].
About CombinatoRx
CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx, please visit [ www.combinatorx.com ].
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates, their clinical potential and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain collaboration partners or additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management's current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
(c) 2009 CombinatoRx, Incorporated. All rights reserved.
